Net Income

Palisade Bio's PALI-2108, a drug targeting IBD at its source, secures a key investment, offering hope for a new era of treatment with fewer side effects.

A new global study shows consumers embrace AI for product research but don't trust it for purchases, revealing a 'Confidence Economy' ruled by transparency.

Blackstone is now the sole institutional backer of AIR Control Concepts, fueling the HVAC leader's rapid growth and strategic expansion into the booming data center market.

A new tri-specific antibody, IM1240, safely hits cancer cells at massive doses in preclinical studies, potentially solving a key toxicity problem in immunotherapy.

Fresh off its 'Fierce 15' win, Recludix Pharma and its billion-dollar Sanofi pact take the spotlight with a novel oral drug for inflammatory diseases.

Backed by the LEGO family's firm, Adapture Renewables secures major U.S. Bank financing to build out its 441 MW Titanium solar portfolio in IL and AR.

Vera Therapeutics' novel IgAN drug gets FDA fast-track review, promising a new at-home treatment for a debilitating autoimmune kidney disease.

Following a pivotal 2024 merger, California BanCorp appoints veteran banker and Chairman David Rainer as CEO, succeeding the retiring Steven Shelton.

With its revolutionary Prime Editing tech showing promise, Prime Medicine faces a pivotal moment at the J.P. Morgan conference. Can it justify its new strategy?

With a device that calms deadly 'cytokine storms,' SeaStar Medical targets vast new markets, but can the small company deliver on its huge promises?

NRG Energy names insider Robert J. Gaudette as its next CEO, signaling strategic continuity as the energy giant navigates a market in transformation.

Kelonia Therapeutics gets the FDA green light to expand trials for its in vivo CAR-T therapy, a single-infusion treatment that could redefine cancer care.

Azitra will present its novel AI-driven skin therapies for rare diseases at Biotech Showcase, seeking crucial funding and partnerships to advance its pipeline.

As Sotera Health prepares for the J.P. Morgan conference, strong financials clash with legal challenges, putting its mission-critical role under scrutiny.

A Tennessee company's patented 1-to-1 CBD and CBDA formula shows promise in fighting inflammation, setting the stage for a new class of FDA-regulated drugs.

New IoT solution from Clarios prevents costly trailer failures and protects cold chain goods by providing real-time battery health insights.

Tidewater Midstream solidifies its position in Alberta with new five-year agreements, promising stable revenue and high utilization at its key Brazeau River facility.

Apogee Enterprises taps a veteran insider as interim CFO after Matthew Osberg's exit coincides with a sharp stock drop and reduced financial guidance.

With positive Phase 2 results for its antibody AP-101, AL-S Pharma targets a key protein in both genetic and sporadic forms of ALS, offering new hope.

New data from a major Swedish study reveals SAGA Diagnostics' Pathlight test can predict colorectal cancer recurrence with remarkable accuracy, changing the game.